Locoregional Stomach Cancer

Gastric Adenocarcinoma

Male, 35 years

Patient Internal ID: 302683160

ICD-10 code

C16.2 Malignant Neoplasm of Body of Stomach

Diagnosis (Incl. Metastases/Stage) and Year

June 2020
Adenocarcinoma of Gastric Body cT3N1Mo G3 (ypT3N3a LV1 R0).

Previous Treatment

Chemotherapy (FLOT4), Surgery (Gastrectomy) + HIPEC, Chemotherapy (Cisplatin + Fluorouracil).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~40 months from diagnosis.

Treatment Provided

Autologous DCV (7 doses) and CIK (9 doses) over a period of 6 months.

Patient Survival/Condition and Year
Date of Review: 15/10/2023

Patient survived 21 months from diagnosis, he had reached a stable disease control, however, he died due to other medical complications. It can be concluded that Immunotherapy, alongside Chemotherapy, Surgery and HIPEC Chemotherapy, benefited for disease control.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok